Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × abemaciclib × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 30 Neoplasm Metastasis 7 Brain Neoplasms 6 Prostatic Neoplasms 4 Neoplasms 4 Glioma 4 Glioblastoma 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Unilateral Breast Neoplasms 2 Triple Negative Breast Neoplasms 2 Sarcoma, Ewing 2 Recurrence 2 Ovarian Neoplasms 2 Neoplasms by Site 2 Meningioma 2 Colorectal Neoplasms 2 Breast Diseases 2 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Kaposi 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Ovarian High Grade Serous Adenocarcinoma 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms, Squamous Cell 1

Interventions

Cyclophosphamide 5 fludarabine 4 Dexamethasone 4 blinatumomab 3 Lenalidomide 3 pembrolizumab 2 fludarabine phosphate 2 Cytarabine 2 venetoclax 1 tislelizumab 1 tisagenlecleucel 1 tetrathiomolybdate 1 tagraxofusp 1 relugolix 1 obinutuzumab 1 nilotinib 1 ixazomib 1 isatuximab 1 inavolisib 1 giredestrant 1 enzalutamide 1 daratumumab 1 abemaciclib 1 Vincristine 1 Transplantation 1 Radiotherapy 1 Neoadjuvant Therapy 1 Monatide (IMS 3015) 1 Methotrexate 1 Melphalan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡